CDX1140-01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (part 1) and in combination with CDX-301 (part 2) or pembrolizumab (part 3) Meeting Abstract
| Authors: | Sanborn, R.; Hauke, R.; Gabrail, N.; O'Hara, M.; Bhardwaj, N.; Bordoni, R.; Gordon, M.; Khalil, D.; Abdelrahim, M.; Marron, T.; Hawthorne, T.; Thomas, L.; Rawls, T.; Rogalski, M.; Alvarado, D.; Vitale, L.; Keler, T.; Yellin, M. |
| Abstract Title: | CDX1140-01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (part 1) and in combination with CDX-301 (part 2) or pembrolizumab (part 3) |
| Meeting Title: | 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 8 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2020 Nov 9-14 |
| Meeting Location: | Virtual |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2020-11-01 |
| Start Page: | A246 |
| Language: | English |
| ACCESSION: | WOS:000616665300394 |
| DOI: | 10.1136/jitc-2020-SITC2020.0405 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 405 -- Source: Wos |
